Table 5.
Distribution of endpoints from the landmark analysis at 5 years (n = 1178)*
| Time to event, y | No. (%) of cumulative DM events |
No. (%) of cumulative GCTF events |
No. (%) of cumulative PCSDs |
||||||
| Control arm | Experiment arm | Total | Control arm | Experiment arm | Total | Control arm | Experiment arm | Total | |
| ≤1 | 1 (1) | 2 (3) | 3 (1.5) | 32 (10) | 28 (11) | 60 (10.5) | — | — | — |
| >1 to 2 | 14 (12) | 6 (8) | 20 (10.2) | 70 (23) | 44 (18) | 114 (19.9) | — | — | — |
| >2 to 3 | 27 (23) | 12 (15) | 39 (19.9) | 182 (56) | 141 (56) | 323 (56.3) | — | — | — |
| >3 to 4 | 35 (30) | 18 (23) | 53 (27.0) | 211 (65) | 155 (62) | 366 (63.8) | — | — | — |
| >4 to 5 | 44 (38) | 30 (38) | 74 (37.8) | 239 (74) | 179 (82) | 418 (72.8) | — | — | — |
| >5 to 6 | 57 (49) | 43 (54) | 100 (51.0) | 259 (80) | 195 (78) | 454 (79.1) | 14 (19) | 11 (20) | 25 (19.2) |
| >6 to 7 | 73 (62) | 48 (61) | 121 (61.7) | 285 (88) | 211 (84) | 496 (86.4) | 22 (30) | 17 (30) | 39 (30.0) |
| >7 to 8 | 84 (72) | 60 (76) | 144 (73.5) | 299 (92) | 222 (89) | 521 (90.8) | 34 (46) | 25 (45) | 59 (45.8) |
| >8 to 9 | 95 (81) | 66 (84) | 161 (84.1) | 311 (96) | 230 (92) | 541 (94.3) | 49 (66) | 35 (63) | 84 (64.6) |
| >9 to 10 | 106 (91) | 73 (92) | 179 (91.3) | 319 (98) | 239 (96) | 558 (97.2) | 59 (80) | 44 (79) | 103 (79.2) |
| >10 to 11 | 110 (94) | 76 (96) | 186 (94.9) | 323 (99) | 242 (97) | 565 (98.4) | 68 (92) | 49 (88) | 117 (90.0) |
| >11 to 12 | 116 (99) | 77 (97) | 193 (98.5) | 323 (99) | 248 (99) | 571 (99.5) | 71 (96) | 53 (95) | 124 (95.4) |
| >12 | 117 (100) | 79 (100) | 196 (100) | 324 (100) | 250 (100) | 574 (100) | 74 (100) | 56 (100) | 130 (100) |
*
Time to event was from the date of random assignment to distant metastasis, general clinical treatment failure, or prostate cancer–specific death. DM = distant metastasis; GCTF = general clinical treatment failure; PCSDs = prostate cancer–specific deaths; — = no PCSDs.